24 May 2014 Posted in News Release By Press Office
Commenting on the adoption of the World Health Assembly resolution, Louise Leong, ABPI Director of R&D, said:
“The ABPI welcomes the recognition made by the World Health Assembly that the antibiotic resistance challenge must be tackled at a global level. We hope that this resolution will lead to greater international coordination and action on the prudent use of antibiotics, as well as on finding incentives and funding solutions that will enable much-needed new antibiotics to be developed for the benefit of patients.”
“New economic incentives need to be introduced as a matter of urgency so that patients can gain access to vital new medicines and so that there can be return on investment and reward for innovation for developing new antibiotics. The current system, where revenue is based on volume of sales, neither supports effective stewardship nor costly development of new antibiotics and has led to a decline in investment in research and development in new antibiotics.
“We applaud the leadership that the UK has shown in moving and supporting the resolution and we look forward to working with the Government in implementing the UK’s five year strategy on antimicrobial resistance.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811